Thank you very much for coming today and sharing your experiences with us.
I'm particularly interested in the First Do No Harm report that you have issued. Can you share with our committee some of the recommendations from that report, especially focused on knowledge gaps and our ability to strengthen the surveillance of prescription drug abuse.